



cancers



an Open Access Journal by MDPI

State-of-the-Art Research on Multiple Myeloma Progression

Guest Editor:

Dr. Shebli Atrash

Levine Cancer Institute,
Charlotte, NC 28204, USA

Deadline for manuscript
submissions:

30 November 2024

Message from the Guest Editor

Multiple myeloma is a type of blood cancer that occurs when malignant plasma cells accumulate in the bone marrow. In recent years, science has made significant progress in understanding the molecular pathways involved in myeloma development and developing new drugs to treat the disease.

One crucial area of research has been the identification of genetic mutations and alterations that contribute to the development of myeloma. Another area of focus has been the development of immunotherapies, which harness the immune system's power to fight cancer.

Bench-to-bedside development is a vital process that enables the development of new therapies for myeloma, leading to improved patient outcomes and survival. The current state-of-the-art therapies in myeloma include immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, T-cell engagers, CAR-T cell therapies, and XPO-1 inhibitors.

The recent advances in myeloma research and drug development offer hope for improved outcomes for patients with this challenging disease.



mdpi.com/si/171881

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI